Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes
DOI: https://doi.org/10.2147/IJN.S366962
IF: 7.033
2022-06-30
International Journal of Nanomedicine
Abstract:Sérgio Scalzo, 1 Anderson K Santos, 1 Heloísa AS Ferreira, 1 Pedro A Costa, 1 Pedro HDM Prazeres, 2 Natália JA da Silva, 1 Lays C Guimarães, 1 Mário de Morais e Silva, 1 Marco TR Rodrigues Alves, 1 Celso TR Viana, 1 Itamar CG Jesus, 1 Alice P Rodrigues, 1 Alexander Birbrair, 2 Anderson O Lobo, 3 Frederic Frezard, 1 Michael J Mitchell, 4 Silvia Guatimosim, 1 Pedro Pires Goulart Guimaraes 1 1 Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; 2 Department of General Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; 3 Department of Materials Engineering, Federal University of Piauí, Teresina, PI, Brazil; 4 Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA Correspondence: Pedro Pires Goulart Guimaraes, Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil, Tel +55 031 3409-2948, Email Introduction: Gene therapy is a promising approach to be applied in cardiac regeneration after myocardial infarction and gene correction for inherited cardiomyopathies. However, cardiomyocytes are crucial cell types that are considered hard-to-transfect. The entrapment of nucleic acids in non-viral vectors, such as lipid nanoparticles (LNPs), is an attractive approach for safe and effective delivery. Methods: Here, a mini-library of engineered LNPs was developed for pDNA delivery in cardiomyocytes. LNPs were characterized and screened for pDNA delivery in cardiomyocytes and identified a lead LNP formulation with enhanced transfection efficiency. Results: By varying lipid molar ratios, the LNP formulation was optimized to deliver pDNA in cardiomyocytes with enhanced gene expression in vitro and in vivo, with negligible toxicity. In vitro, our lead LNP was able to reach a gene expression greater than 80%. The in vivo treatment with lead LNPs induced a twofold increase in GFP expression in heart tissue compared to control. In addition, levels of circulating myeloid cells and inflammatory cytokines remained without significant changes in the heart after LNP treatment. It was also demonstrated that cardiac cell function was not affected after LNP treatment. Conclusion: Collectively, our results highlight the potential of LNPs as an efficient delivery vector for pDNA to cardiomyocytes. This study suggests that LNPs hold promise to improve gene therapy for treatment of cardiovascular disease. Graphical Keywords: lipid nanoparticles, ionizable lipids, pDNA delivery, heart, cardiomyocytes Graphical Cardiovascular diseases (CVD) refer to a group of disorders of blood vessels and the heart. 1–3 Despite all the progress and clinical innovations made over the past decades, CVD still have a high prevalence and represent the leading cause of death worldwide, with a significant impact on the healthcare system costs of many countries. 4,5 With an estimated 17.9 million deaths per year, CVD are considered part of chronic non-communicable diseases, representing approximately 32% of total deaths worldwide in 2019. 3 To address this challenge and to overcome the limitations of conventional therapies, much attention has been given to advances in delivery systems, which are associated with the knowledge of the target's signaling pathways and biological barriers, and are being exploited to develop more effective gene therapies. 4 The potential of gene therapy has provided unprecedented opportunities to explore challenges from early treatments. 4,6 It is also a promising approach to be applied in cardiac regeneration after myocardial infarction and gene modulation for inherited. 7–11 While several preclinical and clinical studies have shown the efficacy of gene therapy in many tissues and cells, the therapeutic efficacy of this approach remains a challenge in the heart tissue. 8 This is likely due to several factors, including nucleic acid degradation, inactivation by serum proteins, loss of therapeutic effect over time, and insufficient delivery to the cardiac tissue. 12 Moreover, the cardiac sarcolemma represents an additional barrier to nucleic acid delivery. 8 Thus, one of the greatest challenges faced is the optimal gene delivery vector, which should be safe, effective, and display selectivity for the cardiac tissue. 11 Both non-viral and recombinant viral delivery methods for gene therapy have now been established for their use in clinical trials. 1 -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology